OverviewRecordsSchemasFilesVersions

Push 29080 records

29,080 records0 files14 MiB total4 types
via nih-clinical-trials/1.0Jun 12, 2026ulv2:1afecdcc134a…ark:12345/ulr1bn5nb6jsbfx.v1.0.0
idnctIdtitlestatussponsorIdbriefSummarycompletionDateconditionsenrollmentCountenrollmentTypephasestartDatestudyTypeurl
NCT00000171NCT00000171Study of Melatonin: Sleep Problems in Alzheimer's DiseaseCOMPLETEDnational-institute-on-aging-niaThis protocol is a multicenter clinical trial of melatonin for sleep disturbances associated with Alzheimer's disease (AD). Frequent nocturnal awakening is a common behavioral symptom of AD. Nighttime wandering and agitated behavior may result in injuries and sleep disruption for caregivers. Alternatives are sorely needed to the currently available sleep medications that have marginal efficacy and serious side effects. Melatonin is a naturally occurring hormone secreted by the pineal gland. It has soporific effects with oral administration and is well tolerated. It enhances sleep in normal older people. Melatonin also may help sleep disturbances associated with AD; however, this remains to be proven.—["Alzheimer Disease","Dyssomnias"]——PHASE3—INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00000171
NCT00000172NCT00000172Placebo Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy Under a Slow-Titration RegimenCOMPLETEDjanssen-lpGalantamine is an experimental drug being evaluated in the United States for the treatment of Alzheimer's disease. Results from previous clinical trials suggest that galantamine may improve cognitive performance in individuals with Alzheimer's disease. It is not a cure for Alzheimer's disease. Nerve cells in the brain responsible for memory and cognitive function communicate using a chemical called acetylcholine. Research has shown that deterioration of cells that produce acetylcholine in the brain affects thought processes. Galantamine is thought to work in two ways to increase the amount of acetylcholine available in the brain. It inhibits an enzyme that breaks down acetylcholine and it also stimulates the nicotinic receptors in the brain to release more acetylcholine.—["Alzheimer Disease"]——PHASE3—INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00000172
NCT00000173NCT00000173A Randomized, Double-Blind, Placebo-Controlled Trial of Vitamin E and Donepezil HCL (Aricept) to Delay Clinical Progression From Mild Cognitive Impairment (MCI) to Alzheimer's Disease (AD)COMPLETEDnational-institute-on-aging-niaThe National Institute on Aging (NIA) is launching a nationwide treatment study targeting individuals with mild cognitive impairment (MCI), a condition characterized by a memory deficit, but not dementia. An NIA-funded study recently confirmed that MCI is different from both dementia and normal age-related changes in memory. Accurate and early evaluation and treatment of MCI individuals might prevent further cognitive decline, including development of Alzheimer's disease (AD). The Memory Impairment Study is the first such AD prevention clinical trial carried out by NIH, and will be conducted at 65-80 medical research institutions located in the United States and Canada. This study will test the usefulness of two drugs to slow or stop the conversion from MCI to AD. The trial will evaluate placebo, vitamin E, and donepezil, an investigational agent approved by the Food and Drug Administration for another use. Vitamin E (alpha-tocopherol) is thought to have antioxidant properties, and was shown in a 1997 study to delay important dementia milestones, such as patients' institutionalization or progression to severe dementia, by about seven months.2004-01["Alzheimer Disease"]——PHASE31999-03INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00000173
NCT00000174NCT00000174Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx)COMPLETEDnovartisThis phase IIIb trial is a prospective, randomized, double-blind, placebo-controlled, 36-month study comparing the length of time of progression from mild cognitive impairment (MCI) to a clinical diagnosis of Alzheimer's disease (AD) in subjects taking Exelon vs. placebo. Exelon is currently under review with the U.S. Food and Drug Administration as a treatment for Alzheimer's disease. The drug has been cleared for marketing in more than 40 countries for Alzheimer's disease to date, including all 15 member states of the European Union, New Zealand, Argentina, Brazil and Mexico. Each subject with MCI will be randomly assigned to treatment with either Exelon or placebo. Subjects assigned to Exelon will receive 1.5 to 6.0 mg bid (twice daily) (3.0 to 12 mg/day) for the majority of the study. At every regular visit scheduled every three months, patients will be given basic efficacy and safety assessments. These assessments will include evaluation of adverse events, vital signs, activities of daily living, and clinical staging scales to determine if the subject may have converted to dementia.—["Alzheimer Disease","Cognition Disorders"]——PHASE3—INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00000174
NCT00000176NCT00000176Alzheimer's Disease Prevention Trial. A Multi-center, Randomized, Double-blind Placebo Controlled Trial of Estrogens to Prevent Alzheimer's Disease and Loss of Memory in Women.COMPLETEDnational-institute-on-aging-niaThis is a three-year study to determine if estrogens can prevent memory loss and Alzheimer's disease in women with a family history of Alzheimer's disease.2007-09["Alzheimer Disease","Memory Disorders"]——PHASE3—INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00000176
NCT00000177NCT00000177Estrogen Hormone ProtocolCOMPLETEDnational-institute-on-aging-niaEstrogen is a hormone that is dominant in the female reproductive system. In women, most estrogen is produced by the ovaries. Men produce estrogen by converting testosterone into estrogen. Because this hormone also has many beneficial effects on brain cells, it currently is being studied as a treatment for Alzheimer's disease. The enzyme that forms the neurotransmitter acetylcholine is promoted in the presence of estrogen. Several very small clinical studies have demonstrated improvement in cognitive function and mood measures in women with Alzheimer's disease who take estrogen.1999-01["Alzheimer Disease"]120—PHASE31995-10INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00000177
NCT00000178NCT00000178Multicenter Trial of Prednisone in Alzheimer's DiseaseCOMPLETEDnational-institute-on-aging-niaThis is a randomized placebo controlled, double blind study. Patients who meet eligibility criteria and decide to participate in the study will be randomly assigned to receive either drug treatment or a placebo. Neither the patients nor the participating investigators will know who is receiving the drugs and who is receiving the placebo. Participation involves 15 outpatient clinic visits over a 68 week period. Patients take study medication at varying doses (the maximum dose is 20 mg daily), along with calcium and vitamin supplements.—["Alzheimer Disease"]——PHASE3—INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00000178
NCT00000179NCT00000179Agitation in Alzheimer's DiseaseCOMPLETEDnational-institute-on-aging-niaAgitation affects 70 to 90 percent of patients with AD. Signs of agitation include verbal and physical aggressiveness, irritability, wandering, and restlessness. These behaviors often make caring for patients at home very difficult. Trazodone and haldol are two of the most commonly prescribed drugs for agitation in AD patients. Behavior management, a non drug approach, has been effective in reducing signs of agitation. Researchers have yet to compare the effectiveness of drug versus non drug therapy to treat agitation in AD patients and determine which is the best treatment. The Alzheimer's Disease Cooperative Study, with funding from the National Institute on Aging, is conducting an agitation treatment program at 21 sites in 16 States. This study will assess which of the above treatments is most effective.—["Alzheimer Disease"]——PHASE3—INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00000179
NCT00001235NCT00001235Biochemical and Genetic Studies in Familial Alzheimer's DiseaseCOMPLETEDnational-institute-of-neurological-disorders-and-stroke-nindsAlzheimer's disease is a condition marked by the deterioration of mental function. The disease usually begins in late middle life and results in death in 5 to 10 years. Patients with Alzheimer's disease typically suffer from memory loss, confusion, and disorientation. The condition has become a major medical and social problem in the United States because of the increasing number of people living beyond the age of 65. The actual cause of Alzheimer's disease is unknown. Researchers believe that Alzheimer's disease, or at least a portion of cases, may be an inherited condition. As a result, many new techniques have been developed to study the genetic causes of Alzheimer's disease and other neurological disorders. Many of these genetic techniques require blood samples and a family pedigree. A pedigree is a chart, similar to a family tree, that shows a patient's family history. The purpose of this study is to collect family and psychosocial information, blood, and biopsy samples from patients with neurological diseases, their families, and normal volunteers. This information gathered will be used to learn more about diseases that affect the brain.2004-02["Alzheimer's Disease","Nervous System Disease"]1500——1988-02OBSERVATIONALhttps://clinicaltrials.gov/study/NCT00001235
NCT00001480NCT00001480The Evaluation and Follow-up of Patients With Memory Disorder and Normal ControlsCOMPLETEDnational-institute-of-mental-health-nimhThe purpose of this study is to evaluate people with mild memory problems, those with dementia, those at risk for developing Alzheimer's disease (AD), and healthy volunteers to identify markers of AD before the changes that occur with the disease begin. The origin and markers of progression for Alzheimer's disease (AD) are relatively obscure. Despite increased understanding of the underlying biology of AD, its clinical diagnosis is still made only after progressive cognitive decline; definitive diagnosis is confirmed at autopsy. This study will examine biomarker changes over time in a distinct cohort of people with an increased risk of developing AD. The study will also identify and track biological changes that occur with progressive dementia and compare those changes to the known cognitive and emotional disturbances that characterize AD. Individuals with a first-degree relative with AD will be recruited into an at-risk cohort. They will be followed and compared to a group of healthy volunteers for a minimum of 8 years.2007-03-31["Alzheimer's Disease","Dementia","Healthy","Memory Disorder"]750——1995-03-21OBSERVATIONALhttps://clinicaltrials.gov/study/NCT00001480
NCT00001549NCT00001549Diagnosis and Natural History Protocol for Patients With Neurological ConditionsCOMPLETEDnational-institute-of-neurological-disorders-and-stroke-nindsThe purpose of this study is to improve understanding of neurological conditions. Patients participating in this study will continue receiving medical care, routine laboratory tests, and diagnostics tests (X-rays, CT-scans, and nuclear imaging), from their primary care physician. Doctors at the NIH plan to follow these patients and offer advice and assistance to their primary care physicians.2006-01["Alzheimer's Disease","Dementia","Movement Disorder","Multiple System Atrophy","Parkinson's Disease"]600——1995-10OBSERVATIONALhttps://clinicaltrials.gov/study/NCT00001549
NCT00001662NCT00001662Tolerability and Primary Efficacy of CX516 in Alzheimer's DiseaseCOMPLETEDnational-institute-of-neurological-disorders-and-stroke-nindsGlutamate is an amino acid released by brain cells that acts to excite other cells. Glutamate attaches to special sites on cells called AMPA (alpha-amino-2,3-dihydro-5 methyl 3-oxo-4-isoxazolepropanoic acid) receptors. The brain cells responsible for releasing glutamate are damaged in Alzheimer's disease and other conditions affecting thinking and reasoning. Researchers would like to see if giving patients a drug that attaches to AMPA receptors improves the symptoms of Alzheimer's disease. CX516 (Ampalex) is a test drug that affects the AMPA receptors. This study will investigate the effectiveness and safety of CX516 on patients with Alzheimer's disease. Patients will be given capsules of CX516 or placebo (sugar pill that neither harms nor helps) for up to 16 weeks in different amounts. The effectiveness of the drug will be measured by neurological tests. Safety will be monitored by frequent check-ups and lab examinations.2005-11["Alzheimer's Disease","Dementia"]40—PHASE21996-12INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00001662
NCT00001917NCT00001917M2 Receptor Measurements in Aging and in Alzheimer's DiseaseCOMPLETEDnational-institute-of-mental-health-nimhThe purpose of this study is to use brain imaging technology to study the effects of aging and Alzheimer's Disease (AD) on a specific type of brain receptor. The brain is made up of cells called neurons. The neurons communicate with one another and secrete chemicals called neurotransmitters. The neurotransmitters bind to specific sites on other neurons called receptors. Acetylcholine (ACh) is a neurotransmitter that binds to ACh receptors. In both aging and AD, the number of neurons that secrete ACh decreases and the function of some ACh receptors changes. This study will use positron emission tomography (PET) scans of the brain to study the effects of age and AD on muscarinic type 2 \[M2\], a type of ACh receptor. Participants in this study will be injected with a radioactive tracer (ligand \[F-18\] FP-TZTP) which binds to \[M2\] receptors. Participants will then undergo a PET scan in order for the density and function of \[M2\] receptors to be studied.2005-04["Alzheimer's Disease","Healthy"]150——1999-04OBSERVATIONALhttps://clinicaltrials.gov/study/NCT00001917
NCT00001933NCT00001933Nefiracetam Therapy of Alzheimer's Type DementiaCOMPLETEDnational-institute-of-neurological-disorders-and-stroke-nindsSome of the thinking difficulties of Alzheimer's patients may be due to a deficiency in a brain chemical called acetylcholine, which helps transmit messages between nerve cells. Nefiracetam is a new drug that stimulates acetylcholine. This study will test whether Nefiracetam can safely improve memory, thinking and activities of daily living in patients with mild to moderate intellectual impairment due to Alzheimer's disease. Patients in the study must have a caregiver and designated representative. Candidates will be given a medical history and physical examination that includes a complete neurologic and neuropsychologic evaluation, blood tests, and an electrocardiogram. A chest X ray and magnetic resonance imaging (MRI) test will be done on patients who have not had these tests within the previous two years. During the 20-week study, each patient will take three pills twice a day for twenty weeks of either Nefiracetame or placebo (sugar pill). Neither the patients nor the doctors will know which patients are getting the drug and which are getting the placebo. Blood and urine tests will be done frequently throughout the study. Patients will be asked to have a spinal tap (on a voluntary basis) to measure the levels of drug in the spinal fluid, and a PET scan (a brain imaging test). At the end of the study, patients who feel they are doing well with no side effects from the drug (or placebo) may be given the option of continuing treatment for another seven months. Animal studies showed that Nefiracetam improved learning impairment and memory in rats with dementia. In a small study of humans, about one-fourth of patients who were given a low dose of the drug had improved intellectual function, and about one-half who received a higher dose improved.2002-01["Alzheimer's Disease"]50—PHASE21999-07INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00001933
NCT00001972NCT00001972Positron Emission Tomography Imaging of Human Brain Phospholipid Metabolism in Relation to Age and DiseaseCOMPLETEDnational-institute-of-neurological-disorders-and-stroke-nindsThe main source of energy for the brain comes from a combination of oxygen and glucose (sugar). For brain cells to function normally they must receive a constant supply of these nutrients. As areas of the brain become more active blood flow into and out of these areas increase. In addition to oxygen and glucose, the brain uses chemical compounds known as phospholipids. These phospholipids make up the covering of nerve cells that assist in the transfer of information from cell to cell. Without phospholipids brain cell activity may become abnormal and cause problems in the nervous system. Certain diseases like Alzheimer's disease and brain tumors can affect blood flow to the brain and change the way the brain metabolizes phospholipids. In addition to diseases, changes in the brain occur with normal healthy aging. This study is designed to use PET scan to measure changes in blood flow and changes in phospholipid metabolism. Using this technique, researchers can improve their understanding of how certain diseases change the shape and function of the brain.2002-08["Alzheimer's Disease","Brain Neoplasm","Niemann Pick Disease"]123——1994-09OBSERVATIONALhttps://clinicaltrials.gov/study/NCT00001972
NCT00001977NCT00001977Cholinergic Modulation of Human Memory and Attention: Functional Neuroimaging StudiesCOMPLETEDnational-institute-of-mental-health-nimhThis study will examine whether enhancing the chemical acetylcholine in the brain can improve memory and attention. It will identify changes in brain function that occur during these cognitive tasks. Animal and human studies have shown that a decrease in acetylcholine may be responsible for some of the cognition deficits in Alzheimer's disease. Conversely, patients taking medications that slow the breakdown of this neurotransmitter have experienced improvements in memory. Normal volunteers and patients with Alzheimer's disease may be eligible for this study of functional brain imaging using positron emission tomography (PET) and magnetic resonance imaging (MRI). These techniques can measure brain activity and identify brain regions involved in memory and attention. Candidates for this study will be screened with a medical and psychiatric history and a physical examination including blood tests, urinalysis, chest X-ray, and electrocardiogram (ECG). Those enrolled will perform memory and attention tasks during PET and MRI studies. The cognition tasks will be repeated twice-once during infusion of saline (a fluid with no drug effect) through a catheter inserted into a blood vessel and again during infusion of physostigmine, a drug that delays the breakdown of acetylcholine. The PET procedure will be completed in one day; the MRI procedure will be done on two different days. During imaging, attention and memory tasks will be presented in short blocks of about 4-minutes duration. They will be repeated in sequence up to 10 times with a few minutes separation. Subjects will be shown pictures of faces or other visual stimuli and asked to decide whether the pictures are the same or different. Information gained from this study may increase knowledge about how acetylcholine affects the brain's response to memory and attention tasks and perhaps lead to better treatments for the cognitive deficits in Alzheimer's disease.2001-04["Alzheimer's Disease","Healthy"]70——2000-01OBSERVATIONALhttps://clinicaltrials.gov/study/NCT00001977
NCT00004845NCT00004845A Multicenter Trial of Rofecoxib and Naproxen in Alzheimer's DiseaseCOMPLETEDnational-institute-on-aging-niaThe primary specific aim of this clinical trial is to determine whether treatment with rofecoxib or naproxen for one year will slow the rate of decline of cognitive function in patients with Alzheimer's disease (AD) as measured by ADAScog.2001-12["Alzheimer Disease"]——PHASE2, PHASE3—INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00004845
NCT00006176NCT00006176Clinical, Molecular and Biochemical Characterization of Familial Encephalopathy With Neuroserpin Inclusion BodiesCOMPLETEDnational-human-genome-research-institute-nhgriThe purpose of this study is to learn more about the medical problems and the genetic factors involved in a recently defined form of inherited dementia called "familial dementia with neuroserpin inclusion bodies (FDNIB)." Abnormal substances in nerve cells of patients with this disease affect brain and nervous system function, causing confusion, memory decline and impaired cognition (thinking ability). Patients also develop movement disorders and, possibly, seizures. Symptoms begin in midlife, between 45 and 55 years of age. Patients with FDNIB and family members 18 years of age or older at risk for the disease may be eligible for this 3-year study. Participants will have a medical and family history and review of medical records; interview with a medical geneticist (specialist in genetics); physical, neurological and psychiatric examinations; and the following tests and procedures: 1. Blood tests to assess general health 2. Chest and skull X-rays 3. Electrocardiogram (EKG)-record of the electrical activity of the heart using electrodes placed on the chest 4. Electroencephalogram (EEG)-record of the electrical activity of the brain using electrodes placed on the head 5. Ultrasound of the abdomen-imaging of abdominal organs using sound waves 6. Brain magnetic resonance imaging (MRI)-imaging of the brain using a strong magnetic field and radio waves 7. Hearing evaluation 8. Assessment of performance of daily living activities 9. Single photon emission computed tomography (SPECT)-imaging of brain metabolism and blood flow using a radioactive substance injected into a vein The evaluation will be done over a 3- to 4-day period. At their completion, participants will meet with a physician and a genetics counselor to discuss the clinically significant findings. Participants may be asked to return for follow-up evaluations every 6 months to a year (depending on the individual's condition) for 3 years.2009-08-04["Familial Dementia With Neuroserpin Inclusion Bodies","Nervous System Heredodegenerative Disorder"]100——2000-08-10OBSERVATIONALhttps://clinicaltrials.gov/study/NCT00006176
NCT00006399NCT00006399Estrogen Modulation Effects on Cholinergic Function in Normal Post-Menopausal Women and Patients With Alzheimer's DiseaseCOMPLETEDnational-center-for-research-resources-ncrrThe goal of this study is to examine whether the administration of estrogen to post-menopausal women and women with mild to moderate Alzheimer's disease will enhance their memory and their capacity for learning.2004-03["Alzheimer Disease"]45—PHASE21999-09INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00006399
NCT00007189NCT00007189Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)COMPLETEDseattle-institute-for-biomedical-and-clinical-researchThe purpose of this trial is to test the ability of the non-steroidal anti-inflammatory medications naproxen and celecoxib to delay or prevent the onset of AD and age-related cognitive decline.—["Alzheimer Disease"]2625—PHASE32001-01INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00007189
NCT00009191NCT00009191The Depression in Alzheimer's Disease Study (DIADS)COMPLETEDjohns-hopkins-universityMajor depression afflicts approximately 25 percent of patients with AD. Depression in AD patients leads to mental suffering, behavioral disturbance (such as aggression), poor cognition, poor self-care, caregiver depression, caregiver burden, and early entry into the nursing home. Since major depression is treatable, this additional disability may be avoidable. The use of antidepressants to treat major depression in AD is supported by two studies, although a third does not show a benefit for antidepressants over placebo. Also, the safety of antidepressant treatment in depressed AD patients is poorly studied. A conclusive study showing that depression reduction in AD can be accomplished safely with antidepressant medications, and that depression reduction is associated with improvements in activities of daily living, non-mood behavioral disturbances, caregiver burden, and caregiver depression would have major clinical and cost implications for the care of the AD patient. This study is a 13-week, double blind, flexible dose, placebo controlled trial of sertraline in the treatment of outpatients with AD and co-morbid major depression. The hypothesis is that antidepressant treatment is superior to placebo in improving mood, in improving cognition, in reducing physical dependency, in reducing caregiver depression, and in reducing caregiver burden. It is also hypothesized that the degree of depression reduction is correlated with these improvements. It is further hypothesized that the safety profile of sertraline when compared to placebo is acceptable, especially with regard to risk of falls, sleep disturbance, and delirium. One hundred community residing outpatients with probable AD who also meet DSM-IV criteria for major depressive episode will be recruited into the study. They will be randomized to sertraline or placebo and followed through weekly telephone contact by an experienced clinical trials team. Outcomes will be assessed every 3 weeks, for a total of four followup data points. Scales assessing the following domains will be used: depression, cognition, behavioral disturbance, physical dependency, delirium, falls, sleep, other side effects, caregiver depression, caregiver burden, caregiver functioning, and caregiver health.2007-11["Alzheimer Disease","Depression"]——PHASE42005-11INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00009191
NCT00009204NCT00009204Serotonergic Pharmacotherapy for Agitation of DementiaCOMPLETEDbruce-pollockThis study is a randomized, double-blind, placebo-controlled, fixed dose study currently being conducted on two geropsychiatric units at Western Psychiatric Institute and Clinic. It seeks to evaluate the short-term safety and efficacy of citalopram and perphenazine in the treatment of 112 patients suffering from behavioral disturbances associated with dementia. Findings from this research may directly lead to improved acute pharmacotherapy for psychosis and behavioral problems in patients diagnosed with dementia. Improved treatment of behavioral complications with reduced side effects would reduce excess disability in patients diagnosed with dementia, allowing them to be maintained in the community for greater periods of time.2002-04["Dementia","Alzheimer Disease","Dementia, Vascular"]——PHASE31995-09INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00009204
NCT00009217NCT00009217Treatment of Behavioral Symptoms in Alzheimer's DiseaseCOMPLETEDnew-york-state-psychiatric-instituteThe optimal strategy for the treatment of behavioral complications in patients with probable Alzheimer's disease (AD) remains unclear. The objective of this study is to evaluate the risk of relapse following discontinuation of haloperidol in patients with Alzheimer's disease (AD) with psychosis or agitation who respond to it. In Phase A of this study, AD outpatients with behavioral complications receive 20 weeks of open haloperidol treatment with an oral dose of 1-5 mg daily, titrated individually to achieve the optimal trade-off between efficacy and side effects. Responders to Phase A participate in Phase B, a 24-week continuation trial in which patients are randomized to continuation haloperidol or placebo. The primary outcome is the time to relapse of psychosis or behavioral disturbance.2004-12["Alzheimer's Disease","Psychosis","Agitation"]44ACTUALPHASE41999-01INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00009217
NCT00010803NCT00010803Ginkgo Biloba Prevention Trial in Older IndividualsCOMPLETEDnational-center-for-complementary-and-integrative-health-nccihThis study will determine the effect of 240mg/day Ginkgo biloba in decreasing the incidence of dementia and specifically Alzheimer's disease (AD), slowing cognitive decline and functional disability, reducing incidence of cardiovascular disease, and decreasing total mortality.2011-07["Dementia","Alzheimer's Disease"]3069ACTUALPHASE32000-10INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00010803
NCT00012831NCT00012831Nurse Managed Clinic for Dementia Patients and Family CaregiversCOMPLETEDus-department-of-veterans-affairsThis study evaluates the effectiveness of a nurse-managed interdisciplinary (nursing and occupational therapy) clinic serving community dwelling dementia patients and their spouse caregivers. It is grounded in a nursing self-care model that guides nurses to identify interventions that fit with the capabilities of individual patients and compensate for their specific deficits. The occupational therapy assessment uses the Allen Cognitive Levels that identify the abilities and deficits of a particular functional level so that the strategies and approaches taught to caregivers can be tailored to the specific needs of the patient.2001-06["Alzheimer's Disease","Caregivers","Dementia"]120ESTIMATED——OBSERVATIONALhttps://clinicaltrials.gov/study/NCT00012831
NCT00012857NCT00012857Pain Management and Behavioral Outcomes in Patients With DementiaCOMPLETEDus-department-of-veterans-affairsDementia illness often co-exists with painful medical conditions associated with aging (e.g., degenerative joint disease, osteoarthritis, skin ulcers, back pain, headaches, cancer, or angina). While the standard practice is pain assessment for all patients, the elderly with dementia have special needs for assessment, management, and evaluation. When they are unable to verbalize pain, objective measurement of their discomfort are possible manifestations of pain. No research relates systemic pain treatment with reduction of negative problematic behaviors in patient dementia.2001-03["Dementia","Alzheimer Disease, Pain","Behavior, Agitation"]66ESTIMATEDPHASE2—INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00012857
NCT00013182NCT00013182Effect of Activity on Sleep of Cognitively-Impaired VeteransCOMPLETEDus-department-of-veterans-affairsSleep-activity rhythm disturbance is a prevalent, disabling symptom in cognitively-impaired (CI) elders. Their nocturnal sleep is light and inefficient with frequent awakenings. Multiple short daytime napping episodes interfere with daytime activity and functioning. Daytime disruptive behaviors, such as pacing, hitting, and cursing are related significantly to sleep-activity rhythm disturbance. Medical treatment for sleep and behavior disturbances with benzodiazepines or antipsychotic medications has proven minimally effective and has serious side effects such as impairments in cognition, memory, coordination, and balance, tolerance and severe rebound insomnia, and tardive dyskinesia.2001-06["Alzheimer's Disease","Sleep Disorders"]90ESTIMATEDNA—INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00013182
NCT00013650NCT00013650Pilot Study of Immunomodulatory Versus Antiinflammatory Therapy in Alzheimer's DiseaseCOMPLETEDnational-institute-of-mental-health-nimhThe purpose of this study is to evaluate the effects of the drug cyclophosphamide (CY) on inflammation and immune responses in individuals with Alzheimer's Disease (AD). Inflammation and immunologic response appear to contribute to neurodegeneration in people with AD. In a process called gliosis, the brain immune cells microglia and astroglia undergo activation and possible proliferation, which promotes neuronal injury and death. Activated microglia and astroglia produce compounds that are cytotoxic to neurons, and they express molecules that greatly amplify immune and inflammatory processes in the brain. Excessive glial activation and proliferation are thought to be pivotal events that hasten the demise of synapses and neurons in AD. Fortunately, increased understanding of immune and inflammatory pathology in AD has provided new opportunities for designing disease-altering treatments for AD. Studies suggest that medications such as nonsteroidal anti-inflammatory drugs (NSAIDs) and immunomodulatory agents may have an important role in altering the course of AD. CY is a potent anti-inflammatory and immunomodulatory drug that inhibits proliferation of immune cells. This study will evaluate the effects of CY on individuals with mild to moderate AD. Participants in this study will be randomly assigned to receive either two different doses of CY or placebo (an inactive pill) for 6 months. Participants who receive placebo during the 6 months will have the option of receiving CY for an additional 6 months. Participants will undergo magnetic resonance imaging (MRI) scans of the brain. Measures of cerebral spinal fluid biomarkers or neurodegeneration, neuroinflammation, and neuroimmune activation will be taken. In addition, peripheral lymphocyte subsets and peripheral markers of inflammation will be assessed.2008-04-21["Alzheimer's Disease"]60—PHASE12001-03-22INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00013650
NCT00013923NCT00013923A Nutritional Brain Metabolic Enhancer for Alzheimer DiseaseCOMPLETEDnational-institute-on-aging-niaThe purpose of this study is to evaluate the effectiveness of a nutritional supplement that has been developed to improve the brain function of a patient with Alzheimer's disease.2005-06["Alzheimer Disease"]40—PHASE2—INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00013923
NCT00015548NCT00015548Comparative Effectiveness of Antipsychotic Medications in Patients With Alzheimer's Disease (CATIE Alzheimer's Disease Trial)COMPLETEDnational-institute-of-mental-health-nimhThe CATIE Alzheimer's Disease Trial is part of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project. The study is for people with Alzheimer's disease who are having trouble with their thinking or behavior. In particular, this study is trying to find out the best treatment for people who have hallucinations (seeing or hearing things that aren't there), delusions (false beliefs), or agitation. The design of the trial helps to increase the chance that participants in the study receive a medication that helps them. The study uses three medications known as atypical antipsychotics (olanzapine, quetiapine, risperidone), which are the newest medications that are currently available for treating these problems. Participants may also receive an antidepressant (citalopram). The trial lasts for 36 weeks. Participants are given a thorough evaluation at no cost to ensure that this study is appropriate. In addition, the caregiver, family member, or friend who comes with the participant will be offered an educational program about Alzheimer's disease.2004-10["Alzheimer's Disease"]450—NA2001-03INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00015548
NCT00017940NCT00017940A Phase I Study of Ex Vivo Nerve Growth Factor Gene Therapy for Alzheimer's DiseaseCOMPLETEDthe-shiley-family-trustThis Phase I clinical trial is the first step in testing gene therapy. This study is called a "Safety/Toxicity" study by the Food and Drug Administration, and primarily aims to determine whether the experimental protocol is safe for humans. It will determine whether the study procedure causes side effects in humans, and may also give us a preliminary sense of whether this will be effective in combating Alzheimer's disease in humans.2003-11["Alzheimer Disease"]8—PHASE1—INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00017940
NCT00018278NCT00018278Verbal Memory ERPs as Indices of Treatment Response in Alzheimer DiseaseCOMPLETEDus-department-of-veterans-affairsThe main purpose of this study is to determine the electrophysiological effects of cholinergic therapy (cholinesterase inhibitors and transdermal nicotine) in Alzheimer disease. The attempt will be to locate electrophysiological markers and predictors of cognitive and clinical treatment response.2001-09["Alzheimer Disease"]——PHASE41998-10INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00018278
NCT00018291NCT00018291Specific Interventions for Agitation in Alzheimer's DiseaseCOMPLETEDus-department-of-veterans-affairsThis study is aimed at investigating specific pharmacological interventions in the treatment of the disruptive, agitated behavior associated with Alzheimer's patients. In addition, it is hoped that specific clinical profiles will be found to predict which treatment is most effective for these particular patients.2005-01["Alzheimer's Disease","Dementia"]——NA2001-01INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00018291
NCT00018343NCT00018343Alzheimer's Disease and Aging: Therapeutic Potential of EstrogenCOMPLETEDus-department-of-veterans-affairsThis study is designed to evaluate the potential beneficial effects of estrogen on cognitive function of women with Alzheimer's Disease.2001-03["Alzheimer's Disease"]——PHASE21998-04INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00018343
NCT00018382NCT00018382Insulin, Neurogenetics and Memory in Alzheimer's Disease: A Novel Therapeutic ApproachCOMPLETEDus-department-of-veterans-affairsThis study examines the use of insulin-sensitizing compounds, as therapeutic agents for cognitive impairment in Alzheimer's disease.2003-03["Alzheimer Disease"]——PHASE21999-10INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00018382
NCT00018473NCT00018473Gene-Environment Interactions in Alzheimer's DiseaseCOMPLETEDus-department-of-veterans-affairsThis study will create Alzheimer 's disease risk profiles for defined combinations of genotypes and environmental exposures. This study will carry out a molecular epidemiologic study to identify genetic and environmental risks factors using state of the art techniques. The following will be done during the course of this study 1) Recruit both Alzheimer's patients and cognitively normal aged veterans. 2) Evaluate gene interaction in Alzheimer's disease. 3) Evaluate gene-environment interactions on the risk of Alzheimer's disease. These procedures should initially address the question as to whether certain genes either independently or synergistically modify the risk of Alzheimer's disease. This study will also determine whether certain environmental factors (smoking, alcohol consumption etc.) can modify the risk of AD and whether this effect is dependent on certain genetic backgrounds. This study will provide information that will be useful in designing therapies, develop risk factor profiles to be further tested in future studies, designating patients for specific therapies based on genetic factors and providing data and genetic material for future studies. This study will also provide a cohort of older and well characterized cognitively normal veterans for prospective genetic epidemiological studies on aging.2004-03["Alzheimer's Disease"]———1999-04OBSERVATIONALhttps://clinicaltrials.gov/study/NCT00018473
NCT00024531NCT00024531Effect of the HMG-CoA Reductase Inhibitor Atorvastatin Calcium, Lipitor, in the Treatment of Alzheimer's DiseaseCOMPLETEDinstitute-for-the-study-of-aging-isoaThe purpose of this study is to assess the clinical benefit of Lipitor, a cholesterol-lowering drug, in the treatment of Alzheimer's disease.2004-08["Alzheimer Disease"]98—PHASE22000-10INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00024531
NCT00029120NCT00029120MRI Contrast Imaging in the Evaluation and Follow-up of Patients With Memory Disorder and Healthy ControlsCOMPLETEDnational-institute-of-mental-health-nimhThe purpose of this study is to examine how a part of the brain called the hippocampus contributes to memory changes that occur with aging and Alzheimer's disease (AD). Memory problems are the most important early symptoms of AD. The hippocampal region of the brain may be responsible for many age- and AD-related memory disorders. This study will use magnetic resonance imaging (MRI) scans to examine the structure, chemical composition, and function of the hippocampus in participants with AD, participants with mild memory problems, participants who are healthy but are at risk for AD, and healthy volunteers. Participants in this study will undergo MRI scans of the brain. During the MRI, participants will perform memory tests to demonstrate hippocampal functioning.2008-04-21["Alzheimer Disease","Dementia","Memory Disorder","Healthy"]450——2001-12-18OBSERVATIONALhttps://clinicaltrials.gov/study/NCT00029120
NCT00034567NCT00034567Alzheimer's Disease Prevention Instrument ProtocolCOMPLETEDnational-institute-on-aging-niaThis project will focus on the development and testing of efficient, cost effective measures that are specifically designed for use in Alzheimer's Disease (AD) primary prevention trials.—["Alzheimer Disease"]650———OBSERVATIONALhttps://clinicaltrials.gov/study/NCT00034567
NCT00034762NCT00034762Efficacy And Safety Of A Flexible Dose Of Risperidone Versus Placebo In The Treatment Of Psychosis Of Alzheimer's Disease.COMPLETEDjohnson-johnson-pharmaceutical-research-development-l-l-cThe purpose of this study is to evaluate the efficacy and safety of risperidone compared with placebo in the treatment of psychotic symptoms in patients with Alzheimer's disease2003-01["Dementia","Alzheimer Disease","Mental Disorders"]473ACTUALPHASE32000-12INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00034762
NCT00035204NCT00035204A Double-blind, Randomized Pilot Study to Evaluate the Effects of Galantamine and Donepezil on Sleep and Attention and Gastrointestinal (GI) Tolerance in Patients With Mild to Moderate Alzheimer's Disease (AD)COMPLETEDjohnson-johnson-pharmaceutical-research-development-l-l-cThe purpose of this study is to evaluate the relative effects of galantamine compared to donepezil (both cholinesteraste inhibitors), on sleep, attention, and gastrointestinal tolerance in patients with Alzheimer's disease.2003-05["Alzheimer Disease"]63ACTUALPHASE4—INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00035204
NCT00036114NCT00036114Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's TypeCOMPLETEDotsuka-pharmaceutical-development-commercialization-incThe purpose of this study is to learn if aripiprazole is safe and effective in the treatment of psychosis associated with dementia of the Alzheimer's type.2003-08["Alzheimer Disease"]——PHASE32000-03INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00036114
NCT00039702NCT00039702SPECT Imaging of Alpha4beta2 Nicotinic Acetylcholine Receptors Using [123I]5-I-A-85380 in Alzheimer's DiseaseCOMPLETEDnational-institute-of-mental-health-nimhThe purpose of this study is to use brain imaging technology to examine the role of certain brain chemicals in individuals with Alzheimer's disease (AD) and in healthy volunteers. Cognitive dysfunction in people with AD is thought to arise from decreased chemical activity in specific parts of the brain. Decreases in alpha4beta2 nicotinic acetycholine receptors (nAChRs) have been found in the brains of people who died with AD; however, the status of this receptor system in living brains remains unclear. This study will use single photon emission computed tomography (SPECT) to study this receptor system in people with AD who have mild to moderate dementia and in healthy volunteers. In addition, this study will examine the relationship between cognitive dysfunction and nAChR deficits in the brains of individuals with AD. Participants with AD will have four clinic visits; healthy volunteers will have three visits. At Visit 1, participants will undergo a medical history, physical examination, and laboratory tests. Healthy volunteers will have a Mini-Mental State Examination (MMSE) cognitive function test. Participants with AD will have a MMSE and measurement of the severity of their dementia. During Visit 2, participants will undergo a magnetic resonance imaging (MRI) scan of the brain. At Visit 3, participants will undergo SPECT imaging. Only participants with AD will participate in Visit 4. During this visit, cognitive testing will be performed.2004-09["Alzheimer Disease"]40——2002-06OBSERVATIONALhttps://clinicaltrials.gov/study/NCT00039702
NCT00040378NCT00040378Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)COMPLETEDfrederick-schmittThe Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.2016-08["Alzheimer Disease"]4246ACTUAL—2002-05OBSERVATIONALhttps://clinicaltrials.gov/study/NCT00040378
NCT00040443NCT00040443Efficacy And Safety Of CX516 (900 mg t.i.d.) In Elderly Participants With Mild Cognitive Impairment. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group 4-week Study.COMPLETEDrespirerxGlutamate is fundamentally involved in learning and memory. Memory loss associated with mild cognitive impairment may be due to loss of glutamate receptors in the aging brain. There is evidence CX516 enhances brain activity by specifically targeting remaining glutamate receptors in the affected portions of the brain. This study will test the safety and efficacy of CX516 in the symptomatic treatment of participants with mild cognitive impairment.2004-06["Mild Cognitive Impairment"]175ACTUALPHASE22002-04INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00040443
NCT00041678NCT00041678Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's TypeCOMPLETEDotsuka-pharmaceutical-development-commercialization-incThe purpose of this study is to learn if aripiprazole is safe and effective in the treatment of psychosis associated with dementia of the Alzheimer's type.2003-03["Alzheimer Disease"]——PHASE32000-01INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00041678
NCT00042172NCT00042172Cognitive Enhancers Explored With PET ImagingCOMPLETEDuniversity-of-iowaThe purpose of this study is to evaluate the effectiveness of donepezil (Aricept) for the treatment of mild cognitive impairment (MCI) in elderly adults. This study will also determine whether adding ginkgo biloba extract (GBE) enhances the effects of donepezil.2004-09["Cognition Disorders","Alzheimer Disease"]40—PHASE42002-06INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00042172
NCT00046358NCT00046358The Effect of Short-Term Statin and NSAID Treatment on CSF Beta-AmyloidCOMPLETEDnational-institute-of-mental-health-nimhThe purpose of this study is to determine whether short-term use of the drugs ibuprofen and lovastatin affects levels of a protein called beta-amyloid in people who are at risk for developing Alzheimer's Disease (AD).2005-08["Alzheimer Disease"]50—PHASE42002-09INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00046358
NCT00051909NCT00051909Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's DiseaseCOMPLETEDeli-lilly-and-companyStudy of an investigational medication for the treatment of Alzheimer's Disease in patients who are not taking Aricept, Reminyl, Exelon.2003-06["Alzheimer's Disease"]200—PHASE22002-11INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00051909
NCT00053599NCT00053599A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial of Simvastatin to Slow the Progression of Alzheimer's DiseaseCOMPLETEDnational-institute-on-aging-niaCLASP is a research study to investigate the safety and effectiveness of simvastatin (a cholesterol lowering drug or statin) to slow the progression of Alzheimer's disease (AD). Statins are commonly used to treat high cholesterol levels, which increase the risk of heart disease and stroke.2007-10["Alzheimer Disease"]400—PHASE32002-12INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00053599
NCT00056225NCT00056225High Dose Supplements to Reduce Homocysteine and Slow the Rate of Cognitive Decline in Alzheimer's Disease (Vitamins to Slow Alzheimer's - VITAL)COMPLETEDnational-institute-on-aging-niaThe purpose of this study is to determine whether reduction of homocysteine levels with high-dose folate (folic acid), B6, and B12 supplementation will slow the rate of cognitive decline in persons with Alzheimer's disease.2007-06["Alzheimer's Disease"]340ACTUALPHASE32003-01INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00056225
NCT00056316NCT00056316Reducing Depression in Dementia CaregiversCOMPLETEDuniversity-of-missouri-st-louisThe purpose of this study was to develop and examine the initial impact of a distance-based intervention for female family dementia caregivers. As stated in the original proposal, the primary hypothesis of the study was that family caregivers who participated in the Video Intervention would show greater reduction in psychological distress (i.e., on measures of depression and emotional distress following problematic patient behaviors) compared to those in the Basic Education condition, and that this effect would be maintained over time (3 and 6 months post-tx).2004-08["Depression"]74ACTUALPHASE1, PHASE22002-01INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00056316
NCT00056524NCT00056524An Open-Label Multicenter Study to Assess the Safety of AVP-923 in the Treatment of Patients With Pseudobulbar Affect.COMPLETEDavanir-pharmaceuticalsThe purpose of this study is to evaluate the long-term safety of AVP-923 in the treatment of Involuntary Emotional Expression Disorder (IEED) also known as Pseudobulbar Affect (episodes of uncontrolled crying and/or laughter).2007-06["Alzheimer's Disease","Stroke","Parkinson's Disease","Traumatic Brain Injury"]600ESTIMATEDPHASE32003-02INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00056524
NCT00056628NCT00056628Study to Evaluate the Effect of Flow-Regulated Ventriculoperitoneal Shunting on Progression of Alzheimer's Disease: An Investigation of the Safety and Effectiveness of the COGNIShunt® CNS Shunt SystemCOMPLETEDeunoeThis is a study of the effect on the progression of Alzheimer's Disease of a surgically implanted shunt (tube) to increase the flow of cerebrospinal fluid and improve the clearance of potential neurotoxins from the fluid bathing the brain.2004-10["Alzheimer Disease"]250—PHASE32001-01INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00056628
NCT00059410NCT00059410Alzheimer's Disease Treatment and Illness Perceptions Survey (TIPS) IICOMPLETEDalzheimer-s-associationThe TIPS Study, or Treatment and Illness Perceptions Survey, is a study funded by the national Alzheimer's Association to learn more about differences between African Americans' and Whites' attitudes, beliefs, and experiences related to Alzheimer's disease (AD). The study involves a one-time 30-minute telephone survey in which participants are asked about a range of topics related to AD, including their personal experiences, their beliefs about the disease's symptoms and risk factors, and their attitude toward possible future treatment options. Information from the survey will be used to develop more culturally sensitive health education and healthcare services for persons with AD.2005-09["Alzheimer Disease"]210——2003-01OBSERVATIONALhttps://clinicaltrials.gov/study/NCT00059410
NCT00062569NCT00062569Reminiscence During Bathing Persons With Alzheimer's Disease at HomeCOMPLETEDnational-institute-of-nursing-research-ninrThis study will evaluate the effectiveness of a 3-week reminiscence intervention applied during bathing persons with Alzheimer's disease (AD) in decreasing resistiveness to care (RTC), relieving patient discomfort, and improving spouse caregiver appraisals of burden, capabilities and confidence while bathing the patient. Reminiscence provides opportunities for the patient to feel good and recall pleasant memories, easily done by caregivers in a home setting. Home visits and telephone calls from trained nurses provide coaching and practice for caregivers for the preliminary phase of this study. Each couple will be enrolled in the study for approximately 9 weeks. The study will recruit 100 patient/spouse caregiver couples randomly divided into one of two groups: reminiscence with coaching, or bathing support (control). Bathing support will be provided to participants in both conditions including: individualized assessment; education regarding bathing techniques for people with dementia; and individualized problem solving. In addition to the bathing support intervention, participants in the experimental group will receive a pleasant memories interview and reminiscence script with coaching for implementation. Caregivers will keep a journal of their experiences in bathing the care recipient.2006-06["Alzheimer Disease"]90ACTUALNA2002-09INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00062569
NCT00063310NCT00063310Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN)COMPLETEDvoyager-pharmaceutical-corporationALADDIN is a research study to investigate the safety and effectiveness of leuprolide (a hormone drug) to improve the cognitive function and slow the progression of Alzheimer's disease (AD). In women leuprolide is commonly used to treat hormone related conditions such as endometriosis and uterine fibroids. The study will include treatment of women 65 years and older with mild to moderate Alzheimer's disease who reside in the community.2006-02["Alzheimer Disease"]90—PHASE22003-03INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00063310
NCT00064870NCT00064870National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)RECRUITINGindiana-universityThe purpose of the Alzheimer's Disease Genetics Study is to identify the genes that are responsible for causing Alzheimer's Disease (AD). One of the ways in which the risk factor genes for late onset AD can be investigated is by identifying and collecting genetic material from families with multiple members diagnosed with AD or dementia.2026-07["Alzheimer Disease","Late Onset Alzheimer Disease","Dementia"]10000ESTIMATED—2002-06OBSERVATIONALhttps://clinicaltrials.gov/study/NCT00064870
NCT00065169NCT00065169Anti-Inflammation in AD: PET Imaging SupplementCOMPLETEDuniversity-of-california-los-angelesThe purpose of this study is to determine whether the anti-inflammatory drug celecoxib can delay the onset of Alzheimer Disease (AD) in people with Age Associated Memory Impairment (AAMI). This study will also evaluate genetic risk and brain structure as potential predictors of mental decline.2005-11["Alzheimer Disease","Dementia"]138—NA2000-11INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00065169
NCT00065689NCT00065689High Intensity Light Therapy in Alzheimer's DiseaseCOMPLETEDnational-center-for-complementary-and-integrative-health-nccihThe purpose of this study is to determine whether bright light improves the sleep, mood, and behavior of persons with Alzheimer's disease and related dementias (AD) who live in long-term care settings and, if so, to determine the best timing for the light therapy. The light levels being used in the study have been shown to improve depression in persons with seasonal affective disorder (SAD) and to relieve sleep problems in persons with jet lag and other body rhythm disturbances. Because persons with AD often will not remain still in front of a fluorescent panel, this project has involved renovations in the study units that provide for even, regulated, high-intensity light in all public areas of the study settings.2005-09["Alzheimer's Disease","Dementia"]107—PHASE32003-03INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00065689
NCT00065767NCT00065767Cognitive and Neurophysiological Effects of Raloxifene in Alzheimer's DiseaseCOMPLETEDuniversity-of-wisconsin-madisonThe aim of this study is to determine the effectiveness of treatment with raloxifene, an estrogen-like medication approved by the Food and Drug Administration for the treatment of osteoporosis, in improving memory and the ability to live independently in postmenopausal women with Alzheimer's disease.2005-03["Alzheimer Disease"]20—PHASE2, PHASE32001-09INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00065767
NCT00066157NCT00066157Alzheimer's Disease: Therapeutic Potential of EstrogenCOMPLETEDuniversity-of-wisconsin-madisonThis is a 15-month study to determine the effectiveness of hormone replacement therapy in improving memory and the ability to live independently in postmenopausal women with Alzheimer's disease.2007-12["Alzheimer Disease"]42ACTUALPHASE2, PHASE32001-09INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00066157
NCT00071721NCT00071721A Randomized, Double-Blind, Placebo-Controlled Trial of Valproate to Attenuate the Progression of Alzheimer's Disease (AD)COMPLETEDalzheimer-s-disease-cooperative-study-adcsThe purpose of this trial is to demonstrate whether valproate therapy delays the emergence of agitation and/or psychosis in outpatients with probable Alzheimer's disease (AD) who have not experienced agitation and psychosis in their illness. A secondary aim is to determine whether valproate therapy delays the progression of cognitive and functional measures of the illness. This trial will also assess the tolerability and safety of low-dose, long-term valproate therapy. Valproate, an anticonvulsant drug, was selected because of its possible symptomatic efficacy for agitation in AD, known safety profile in numerous clinical populations, and in view of recent data supporting its neuroprotective potential in AD.2009-12["Alzheimer Disease"]313ACTUALPHASE32003-10INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00071721
NCT00073658NCT00073658Continuation Pharmacotherapy for Agitation of DementiaCOMPLETEDuniversity-of-pittsburghThis study will compare the safety and effectiveness two medications, citalopram (Celexa®) and risperidone (Risperdal®).2005-06["Dementia"]137—PHASE22000-01INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00073658
NCT00074529NCT00074529A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-0677 25 mg in Slowing the Progression of Alzheimer's DiseaseCOMPLETEDmerck-sharp-dohme-llcAn investigational drug (MK0677) will be studied to determine whether it helps the memory and cognition of patients with Alzheimer's Disease.2006-01["Alzheimer's Disease"]512ACTUALPHASE22003-10INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00074529
NCT00076440NCT00076440Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 StudyCOMPLETEDvoyager-pharmaceutical-corporationALADDIN is a research study to investigate the safety and effectiveness of leuprolide (a hormone drug) to improve the cognitive function and slow the progression of Alzheimer's disease (AD) in men 65 years and older with mild to moderate Alzheimer's disease who reside in the community.2007-03["Alzheimer Disease"]90—PHASE22003-12INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00076440
NCT00082602NCT00082602Galantamine ER Open Label Rapid Dose Escalation Trial in Alzheimer's DiseaseCOMPLETEDjohnson-johnson-pharmaceutical-research-development-l-l-cThe purpose of this study is to evaluate the safety and tolerability of an extended release formulation of the drug galantamine using a rapid dose escalation regimen.2005-04["Alzheimer's Disease"]83ACTUALPHASE32004-05INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00082602
NCT00083421NCT00083421Effects of ONO-2506PO in Patients With Alzheimer's DiseaseCOMPLETEDono-pharma-usa-incThe purpose of this study is to establish the presence of an effect of treatment with ONO-2506PO in patients with Alzheimer's Disease, based upon cognitive and global scales.2007-07["Alzheimer's Disease"]647ACTUALPHASE22004-06INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00083421
NCT00083590NCT00083590A Multi-Center, Double-Blind, Placebo-Controlled Therapeutic Trial to Determine Whether Natural Huperzine A Improves Cognitive FunctionCOMPLETEDnational-institute-on-aging-niaThe present study will evaluate the safety and efficacy of the Chinese herb huperzine A in the treatment of Alzheimer's disease (AD) in a randomized controlled trial of its effect on cognitive function.2007-11["Alzheimer Disease"]150ESTIMATEDPHASE22004-04INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00083590
NCT00086138NCT00086138Depression in Alzheimer's Disease (DIADS-2)COMPLETEDjohns-hopkins-universityThe purpose of this study is to learn whether treating individuals with Alzheimer's disease and depression with the anti-depressant medication sertraline (Zoloft) is helpful to people with Alzheimer's disease and to their families and caregivers.2009-07["Alzheimer's Disease","Depression"]131ACTUALPHASE2, PHASE32004-07INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00086138
NCT00087789NCT00087789A Phase I, Dose-Escalating Study to Assess the Safety and Tolerability of CERE-110 [Adeno-Associated Virus (AAV)-Based Vector-Mediated Delivery of Beta-Nerve Growth Factor (NGF)] in Subjects With Mild to Moderate Alzheimer's DiseaseCOMPLETEDsangamo-therapeuticsThis is a Phase I clinical study to assess the safety, tolerability and biologic activity of in vivo AAV-mediated delivery of CERE-110. Up to 12 subjects will receive open label CERE-110 in dose-escalating fashion. All subjects will receive bilateral, stereotactic injections of CERE-110 for a total of four (Dose A and B) and six (Dose C) injections to target the basal forebrain region of the brain containing the nucleus basalis of Meynert (NBM). All study participants will be observed for a 24-month period and then followed annually.2010-05["Alzheimer's Disease"]10ACTUALPHASE12004-06INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00087789
NCT00088387NCT00088387Glycogen Synthetase Kinase 3 (GSK-3) Inhibition in Alzheimer's DiseaseCOMPLETEDnational-institute-of-neurological-disorders-and-stroke-nindsThis study will examine the effect of the drugs lithium and divalproex (Depakote) on tau proteins, a type of protein in the brain and spinal fluid that are altered in patients with Alzheimer's disease. Both drugs are approved by the Food and Drug Administration to treat mood disorders, and both have been shown in animal studies to decrease the amount of altered tau protein. This study will determine whether lithium alone or in combination with divalproex reduces the altered tau protein in the spinal fluid of patients with Alzheimer's disease. Patients with Alzheimer's disease who are between 40 and 90 years of age may be eligible for this study. Candidates are screened with a medical history and physical examination, neurologic and neuropsychological evaluation, blood and urine tests, electrocardiogram (EKG), and, if needed, a magnetic resonance imaging (MRI) scan of the brain. Participants undergo the following tests and procedures: * Drug treatment: Patients take study drugs for 6 weeks. * Weekly clinic visits: Patients come to the clinic once a week for a physical examination, blood and urine tests, a review of drug side effects, and to receive the next week's supply of medications. * Lumbar puncture (spinal tap): Patients have a lumbar puncture at study weeks 2, 4, and 6 to measure various brain chemicals and tau proteins in the cerebrospinal fluid (CSF), which bathes the brain and spinal cord. For this test, a local anesthetic is given and a needle is inserted in the space between the bones in the lower back where the CSF circulates below the spinal cord. A small amount of fluid is collected through the needle. * Follow-up visit: Two weeks after completing the study medication, patients return to the clinic for a final evaluation, including a physical examination and blood and urine tests.2005-03["Alzheimer Disease"]35—PHASE22004-07INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00088387
NCT00088751NCT00088751Treatment Study for Frontotemporal DementiaCOMPLETEDnational-institute-of-neurological-disorders-and-stroke-nindsObjectives. The proposed clinical study has two goals: First, to assess the efficacy of a central nervous system stimulant and an atypical antipsychotic in treating the behavioral symptoms of FTD and second, to further characterize the biological markers, including genetic, imaging, and CSF proteins, of FTD in relation to our existing group of Alzheimer's patients. Rationale. Frontotemporal dementia (FTD) is increasingly recognized as an important neuropsychiatric disorder. Symptoms of FTD include disinhibition, impulsivity, apathy, affective lability, and language dysfunction. The clinical syndrome is associated with frontal and/or anterior temporal atrophy on imaging and autopsy. Levels of the CSF proteins tau and (Beta)-amyloid 1-42, shown to have diagnostic utility in patients with Alzheimer's Disease (AD), have also been found to be abnormal in FTD. FTD is less associated with APOE genotype than AD, however some familial cases of FTD are associated with specific mutations in the gene encoding the tau protein. Currently, no treatments have been proven to be effective for altering the course or clinical symptoms of FTD. Design. Study subjects will include 50 male and female patients with mild-moderate frontotemporal dementia recruited from participants in NINDS protocol 02-N-0001. In a double-blinded crossover 11-week study without a placebo control, patients will be treated with a stimulant (dextroamphetamine) and an atypical antipsychotic (quetiapine). The primary outcome measures will be the Neuropsychiatric Inventory and the Clinical Global Impression of Change. Cerebrospinal fluid, cognitive and genetic measures, brain MRIs, and side effects scales will also be collected.2009-06-01["Frontotemporal Lobar Degeneration"]20——2004-07-23OBSERVATIONALhttps://clinicaltrials.gov/study/NCT00088751
NCT00089882NCT00089882Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IICOMPLETEDnational-institute-on-aging-niaThe REVEAL II study provides healthy adult children and siblings of Alzheimer's disease patients with genetic testing and information about their own chances of developing the disease. The study will compare a condensed education and counseling program to the current more extensive program.2006-09["Alzheimer Disease"]360——2003-05OBSERVATIONALhttps://clinicaltrials.gov/study/NCT00089882
NCT00090116NCT00090116A Randomized, Double-Blind,Placebo-Controlled Evaluation of the Safety and Efficacy of Neramexane Monotherapy in Patients With Moderate to Severe Dementia of the Alzheimer's TypeCOMPLETEDforest-laboratoriesMemory loss and difficulties with thinking associated with Alzheimer's disease may be due to chronic release of a brain chemical called glutamate. Glutamate helps transmit messages between nerve cells through interaction with a certain type of receptor (N-methyl-D-aspartate, NMDA) on the cell. Neramexane is a new drug that blocks the effects of excessive glutamate at the receptor (NMDA receptor antagonist).2005-03["Alzheimer's Disease"]400—PHASE32003-03INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00090116
NCT00090402NCT00090402Fish Oil and Alpha Lipoic Acid in Mild Alzheimer's DiseaseCOMPLETEDoregon-health-and-science-universityThe purpose of this study is to determine the effect of fish oil and the antioxidant alpha lipoic acid on factors in the blood that are associated with the progression of Alzheimer's Disease (AD).2007-08["Alzheimer's Disease","Oxidative Stress","Dementia","Hyperlipidemia","Inflammation"]39ACTUALPHASE1, PHASE22004-04INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00090402
NCT00093951NCT00093951A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase II Study of the Efficacy and Safety of SGS742 in Subjects With Mild to Moderate Alzheimer's DiseaseCOMPLETEDsaegis-pharmaceuticalsThe purpose of this trial is to determine the effect of a new drug, SGS742, on memory and cognition in patients with mild to moderate Alzheimer's disease.2007-09["Alzheimer's Disease"]280—PHASE22004-04INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00093951
NCT00095719NCT00095719A Safety & Tolerability Study of Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With DementiaCOMPLETEDotsuka-pharmaceutical-development-commercialization-incThe purpose of this trial is to test the safety \& tolerability of intramuscular aripiprazole in acutely agitated patients diagnosed with Dementia.2005-03["Dementia","Alzheimer's Disease"]125—PHASE32003-12INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00095719
NCT00096473NCT00096473A 24 Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Donepezil Hydrochloride (E2020) in Patients With Severe Alzheimer's Disease Followed by a 12 Week Open-Label Extension PeriodCOMPLETEDeisai-incDonepezil hydrochloride (Aricept) has been approved to treat symptoms associated with mild to moderate Alzheimer's disease (AD). Aricept has been shown to improve the memory and thinking abilities, activities of daily living and global function in patients. The purpose of the study is to further investigate the effectiveness and safety of donepezil in patients with severe Alzheimer's disease. Donepezil is thought to work in the brain by increasing the levels of an important brain chemical called acetylcholine. This chemical helps a person's memory to work better.2005-09["Alzheimer's Disease","Dementia"]229ACTUALPHASE32001-01INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00096473
NCT00097916NCT00097916A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Memantine in Non-Institutionalized Agitated Patients With Moderate to Severe Alzheimer's DiseaseCOMPLETEDforest-laboratoriesAbout 65% of patients with severe Alzheimer's Disease (AD) will have symptoms of agitation. There are drawbacks associated with the currently available therapeutic interventions for agitation associated with Alzheimer's Disease. In a recent trial, in the group of patients with moderate to severe AD treated with memantine, there were fewer incidences of agitation. It is hypothesized that memantine will be effective in reducing the symptoms of agitation associated with moderate to severe Alzheimer's Disease.2006-04["Alzheimer's Disease"]34ACTUALPHASE32004-09INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00097916
NCT00099242NCT00099242Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's DiseaseCOMPLETEDnovartis-pharmaceuticalsThe goal of this research study is to evaluate the safety and efficacy of the rivastigmine transdermal patch in patients with probable Alzheimer's Disease.2006-01["Alzheimer's Disease","Dementia, Alzheimer Type"]1040—PHASE32003-11INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00099242
NCT00099567NCT00099567Metabolic Syndrome, Inflammation, and Risk of Cognitive DeclineCOMPLETEDnational-institute-on-aging-niaThe purpose of this study is to determine if the metabolic syndrome is a risk factor for cognitive decline and if this association is modified by inflammation.2002-12["Cognitive Decline"]2632——1997-01OBSERVATIONALhttps://clinicaltrials.gov/study/NCT00099567
NCT00099710NCT00099710A Phase II, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of Two Doses of Curcumin C3 Complex Versus Placebo in Patients With Mild to Moderate Alzheimer's DiseaseCOMPLETEDjohn-douglas-french-foundationThe purpose of this study is to examine the safety and tolerability of curcumin, and to determine its effect on patients with mild to moderate Alzheimer's Disease (AD).2007-12["Alzheimer's Disease"]33ESTIMATEDPHASE22003-07INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00099710
NCT00100282NCT00100282Single Dose Escalation Safety Study of PPI-1019 in Patients With Mild-Moderate Alzheimer's DiseaseCOMPLETEDpraecis-pharmaceuticals-incThis is a multi-center, double-blind, inpatient study followed by outpatient, placebo-controlled, single-dose, dose-escalation evaluation of the safety and tolerability of PPI-1019 in patients with mild-moderate Alzheimer's disease (AD). Up to 12 sequential cohorts of 8 patients (6 active and 2 placebo) will be given a single PPI-1019 dose intravenously (IV) over 1 minute in order to determine a maximum tolerated dose (MTD). The MTD will be the dose immediately below the not-tolerated dose.2005-06["Alzheimer's Disease"]125—PHASE12003-05INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00100282
NCT00100334NCT00100334Multiple Dose Safety and Preliminary Pharmacodynamic Study of PPI-1019 in Subjects With Mild-Moderate Alzheimer's DiseaseCOMPLETEDpraecis-pharmaceuticals-incThis is a single-center, double-blind, inpatient study followed by an outpatient, placebo-controlled, multiple-IV injection evaluation of the safety and tolerability of PPI-1019 in subjects with mild-moderate Alzheimer's disease (AD). The primary objective of the study is to assess the safety of multiple IV injections of PPI-1019 in subjects with mild-moderate Alzheimer's disease.2005-08["Alzheimer's Disease"]24—PHASE1, PHASE22004-12INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00100334
NCT00103649NCT00103649A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 18-Month Study of the Efficacy of Xaliproden in Patients With Mild-to-Moderate Dementia of the Alzheimer's TypeCOMPLETEDsanofiThe purpose of this study is to assess xaliproden's potential capacity of slowing the deterioration of cognitive and global functions in patients with mild to moderate Alzheimer's disease. The patients participating in this study will take orally once daily xaliproden or placebo (inactive substance pill).2007-10["Alzheimer Disease"]1306ACTUALPHASE32003-11INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00103649
NCT00104013NCT00104013A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 18-Month Study of the Efficacy of Xaliproden in Patients With Mild-to-Moderate Dementia of the Alzheimer's TypeCOMPLETEDsanofiThe purpose of this study is to assess xaliproden's potential capacity of slowing the deterioration of cognitive and global functions in patients with mild to moderate Alzheimer's disease. The patients participating in this study will take orally once daily xaliproden or placebo (inactive substance pill).2007-11["Alzheimer Disease"]1455ACTUALPHASE32003-11INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00104013
NCT00104273NCT00104273A 1-Year, Double-Blind, Randomized, Placebo-Controlled, Study of Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Dementia of the Alzheimer's TypeCOMPLETEDteva-branded-pharmaceutical-products-r-d-incThe purpose of this study is to evaluate the safety, tolerability, and efficacy of two dose levels of rasagiline mesylate versus placebo in patients with mild-to-moderate Alzheimer's Disease who are taking Aricept.—["Dementia","Alzheimer's Disease"]376ACTUALPHASE22004-08INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00104273
NCT00104442NCT00104442Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's DiseaseCOMPLETEDnovartisAlzheimer's disease is a medical illness that damages the brain and causes problems with memory, mood and behavior. A substance called acetylcholine (ACh), which is naturally produced in the body, plays an important role in the normal functioning of the brain. In subjects with Alzheimer's disease, the level of ACh is greatly reduced. Currently, there are three commonly prescribed drugs used for treating the symptoms of Alzheimer's disease by helping to maintain the level of ACh in the brain. This study will evaluate how much each of these drugs changes the levels of certain brain chemicals that are known to, or may play an important role in, Alzheimer's disease and its symptoms.2006-04["Alzheimer's Disease"]80—PHASE42003-10INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00104442
NCT00105547NCT00105547Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment With MPC-7869 on Measures of Cognition, Activities of Daily Living and Global Function in Subjects With Mild Dementia of the Alzheimer's TypeCOMPLETEDmyrexis-incThe purpose of the study is to evaluate the change in cognitive ability and activities of daily living in patients with Alzheimer's disease (AD) as measured by specific evaluations during 18 months of dosing.2008-05["Alzheimer Disease","Dementia"]1600ACTUALPHASE32005-02INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00105547
NCT00105612NCT00105612Improving Informed Consent in Alzheimer's Disease ResearchCOMPLETEDnational-institute-on-aging-niaThe purpose of this trial is to test whether a memory and organizational aid in the form of a document that summarizes and simplifies a study's key points can improve the decision-making abilities and competency of mild to early moderate Alzheimer's disease (AD) patients.2007-03["Alzheimer's Disease","Aging"]110—NA2004-09INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00105612
NCT00105638NCT00105638A Telehealth Education Program for Caregivers of Veterans With DementiaCOMPLETEDus-department-of-veterans-affairsThis study was designed to evaluate the impact of a Telehealth Education Program (TEP) on outpatient veterans with moderate to severe dementia and their spouse caregivers. The TEP is a program of education, coping skills, problem solving and support presented to caregivers of veterans with dementia by teleconference in 10 weekly, one-hour sessions. The TEP was based on a stress and coping model aimed to enhance the knowledge, skills and feelings of support of the caregivers who participated.2007-04["Dementia","Alzheimer Disease"]160ESTIMATEDNA2005-09INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00105638
NCT00106899NCT00106899Alzheimer's Disease Neuroimaging InitiativeCOMPLETEDalzheimer-s-disease-cooperative-study-adcsThe purpose of this study is to examine how brain imaging technology can be used with other tests to measure the progression of mild cognitive impairment (MCI) and early Alzheimer's disease (AD). This information will aid future clinical trials by providing a standard assessment tool to measure the effects of treatments being studied.2011-06["Alzheimer's Disease"]818ACTUAL—2005-07OBSERVATIONALhttps://clinicaltrials.gov/study/NCT00106899
NCT00110552NCT00110552Effects of a Cognitive Enhancer on Memory and Cognitive PerformanceCOMPLETEDoregon-health-and-science-universityThe purpose of this study is to determine the effectiveness of the herb sage in improving the mental function of individuals with Alzheimer's disease. Study hypothesis: The administration of sage will improve cognitive function in patients with mild Alzheimer's disease.2014-10["Alzheimer Disease"]111ACTUALPHASE12005-07INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00110552
NCT00112073NCT00112073A Phase IIA, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Immunogenicity Trial of AAB-001 in Patients With Mild to Moderate ADCOMPLETEDjanssen-alzheimer-immunotherapy-research-development-llcThe purpose of this study is to assess the safety and tolerability of multiple doses of AAB-001 passive immunization in patients with mild to moderate Alzheimer's disease (AD).2008-12["Alzheimer's Disease"]234ACTUALPHASE22005-04INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00112073
NCT00117403NCT00117403Evaluation of the Safety, Tolerability and Impact on Biomarkers of Anti-Oxidant Treatment of Mild to Moderate Alzheimer's DiseaseCOMPLETEDnational-institute-on-aging-niaThe purpose of this study is to examine the safety and effectiveness of two anti-oxidant treatment regimens in patients with mild to moderate Alzheimer's disease. The anti-oxidant treatments include vitamin E + C + alpha-lipoic acid, and Coenzyme Q (CoQ).2007-09["Alzheimer's Disease"]75ESTIMATEDPHASE12006-01INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00117403
NCT00119561NCT00119561Testing the Effectiveness of Telephone Support for Dementia CaregiversCOMPLETEDus-department-of-veterans-affairsThe primary goal of the study is documentation of effectiveness of telephone support groups to reduce caregiver burden and stress. Caregivers who participate in intervention (Telephone Support) should experience lower levels of stress, burden and health care utilization (lower use of psychotropic drugs, fewer scheduled/unscheduled medical visits, lower rates of institutionalization, more efficient use of time in managing care recipient problems) compared to those caregivers in Usual Care.2014-01["Dementia","Alzheimer Disease"]154ACTUALNA2005-02INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00119561
NCT00120874NCT00120874Memantine and Comprehensive, Individualized, Patient Centered Management of Alzheimer's Disease: A Randomized Controlled TrialCOMPLETEDnyu-langone-healthThe purpose of this study is to determine whether a comprehensive, individualized management approach with caregiver training and medication with memantine will alleviate symptoms in community dwelling patients with moderate to severe Alzheimer's disease.2011-11["Alzheimer's Disease"]20ACTUALPHASE42006-08INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00120874
NCT00130429NCT00130429Phase II Randomised, Double Blind, Placebo Controlled, Parallel Group Study to Investigate the Safety, Effect on Cognition and Pharmacokinetic Profile of PYM50028 in Subjects With Mild Dementia of the Alzheimer's TypeCOMPLETEDphytopharmThe purpose of this study is to assess the effect of PYM50028 administered once daily for up to 12 weeks on the memory and other faculties of subjects with dementia due to Alzheimer's disease.2005-09["Alzheimer's Disease"]250—PHASE22004-01INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00130429
NCT00141661NCT00141661A Double-Blind, Randomized, Placebo-Controlled, Phase IIa, Multiple Dose, Multicenter Study in Subjects With Mild to Moderate Dementia of the Alzheimer's Type to Evaluate the Safety and Tolerability of Two 10-Week Dose Regimens of Orally-Administered PF-04494700COMPLETEDpfizerA 10-week safety and tolerability study of a potential treatment for mild to moderate Alzheimer's disease.2006-06["Alzheimer Disease"]67ACTUALPHASE22005-10INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00141661